AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. TEVA
  4. [SCHEDULE 13G] Teva Pharmaceutical Industries Limited American SEC Filing

[SCHEDULE 13G] Teva Pharmaceutical Industries Limited American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Filing content is currently unavailable.

Source:

Stock TEVA logo
Teva Pharm

NYSE:TEVA

TEVA Rankings

#570 Ranked by Market Cap
N/A Ranked by Dividends

TEVA Latest News

Aug 28, 2025
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) � First Generic GLP-1 Indicated for Weight Loss
Aug 6, 2025
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
Jul 30, 2025
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
Jun 26, 2025
Teva Releases Q2 2025 Aide Memoire
Jun 25, 2025
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

TEVA Latest SEC Filings

Aug 6, 2025
[SCHEDULE 13G/A] Teva Pharmaceutical Industries Limited American SEC Filing
Aug 5, 2025
[Form 4] Teva Pharmaceutical Industries Limited American Insider Trading Activity
Aug 1, 2025
[144] Teva Pharmaceutical Industries Limited American SEC Filing
Aug 1, 2025
[144] Teva Pharmaceutical Industries Limited American SEC Filing
Jul 30, 2025
[10-Q] Teva Pharmaceutical Industries Limited American Quarterly Earnings Report

TEVA Stock Data

20.82B
1.15B
0%
66.16%
4.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Israel
TEL AVIV